No consensus on EU-wide review of clinical trial applications
This article was originally published in Scrip
Executive Summary
European pharmaceutical industry association EFPIA wants the European Commission to consider allowing centralised review of clinical trial authorisation (CTA) applications. But the procedure, it says, should complement the present regulatory framework and not replace it.